NH HEALTH: INSIDE INFORMATION DELAY IN PUBLICATION OF THE 2023 ANNUAL RESULTS;POSTPONEMENT OF BOARD MEETING;AND SUSPENSION OF TRADING
Institutional Owners May Consider Drastic Measures as New Horizon Health Limited's (HKG:6606) Recent HK$651m Drop Adds to Long-term Losses
Key Insights Institutions' substantial holdings in New Horizon Health implies that they have significant influence over the company's share price 51% of the business is held by the top 9 shareholder
Novartis Health (06606.HK) plans to hold a board meeting on March 28 to consider and approve the annual results
Glonghui, March 18, 丨 Novartis Health (06606.HK) announced that the board of directors meeting will be held on March 28, 2024 (Thursday) to consider and approve (among other things) the results and announcements of the Company, its subsidiaries and consolidated affiliated entities for the year ended 31 December 2023, and to deal with other matters.
NH HEALTH: NOTICE OF BOARD MEETING
Is It Too Late To Consider Buying New Horizon Health Limited (HKG:6606)?
New Horizon Health Limited (HKG:6606), is not the largest company out there, but it saw a decent share price growth of 14% on the SEHK over the last few months. The recent rally in share prices
Changes in Hong Kong stocks | Minimally Invasive Brain Science (02172) rose more than 5%, leading medical device stock institutions optimistic about the future prospects of overseas expansion of domestic medical devices
The increase in medical device stocks increased in the afternoon. As of press release, Minimally Invasive Brain Science (02172) rose 6.46% to HK$9.4; Chunli Healthcare (01858) rose 4.61% to HK$9.31; Haohai Biotech (06826) rose 3.71% to HK$34.95; and Novi Health (06606) rose 2.35% to HK$18.28.
Changes in Hong Kong stocks | Novartis Health (06606) rose more than 11%. Last year's results continued to exceed expectations, and the volume and price of the three major products rose sharply
Novartis Health (06606) rose more than 11%. As of press release, it rose 11.19% to HK$17.68, with a turnover of HK$349.31 million.
[Broker Focus] Zhongtai Securities maintains Novartis Health (06606) “buy” rating, annual sales growth exceeding expectations
Jinwu Financial News | According to the Zhongtai Securities Report, in 2023, Novartis Health (06606) Chang Weiqing series products are expected to achieve operating revenue of 1,193 billion yuan, an increase of 235% over the previous year, and is expected to achieve confirmed revenue of 1.040,800 copies, an increase of 188% over the previous year. At present, the company's sales, marketing, operation and R&D management systems in the colorectal cancer early screening market have all entered steady development, which is enough to effectively support vertical and horizontal commercial expansion. At the same time, Chang Weiqing's entry and volume in public hospitals have accelerated markedly, laying the foundation for Chang Weiqing's market penetration target of 5% in 2025. 2023
Changes in Hong Kong stocks | Novartis Health (06606) is expected to achieve gross profit of more than 5% after earnings, and is expected to achieve gross profit of over 1.8 billion yuan in 2023. The current year will achieve profit after tax
The Zhitong Finance App learned that Novartis Health (06606) rose by more than 5%. As of press release, it had risen 5.05% to HK$18.32, with a turnover of HK$9.402,900. According to the news, Novartis Health issued an announcement. According to the median financial data before the audit, as of December 31, 2023, the Group's total annual revenue reached RMB 2.01 billion, an increase of 164% over 2022, an increase of 26 times over 2020, and cash payments of over RMB 1.4 billion. The company achieved annual gross profit of RMB 1.84 billion, achieved profit after tax in the first year, group cash balance and specific financial assets
Selected announcements: China CITIC Bank's net profit last year increased 8% year on year; CIMC expects net profit to more than double last year
Nuohui Health is profitable, with an estimated annual gross profit of about 1,888 billion yuan to 1,883 billion yuan, an increase of 179.9% to 190% over the previous year; China Unicom's 5G users increased net month-on-month by 5.082 million in December last year.
New Horizon Health Forecasts Up to 168% Rise in 2023 Revenue
New Horizon Health (HKG:6606) expects a 158.9% to 168.2% year-over-year rise in revenue for the year ended Dec. 31, 2023, to between 1.98 billion yuan and 2.05 billion yuan. The developer of screening
Novartis Health (06606.HK): Total revenue is expected to increase by 158.9% to 168.2% year-on-year in 2023
On January 22, GLONGHUI Health (06606.HK) announced that the Group's total revenue for the year ended December 31, 2023 is expected to be between RMB 1,9788 million and RMB 2,0498 million, an increase of 158.9% to 168.2% over approximately RMB 764.4 million for the year ended December 31, 2022. The Group's gross profit forecast for the year ended 31 December 2023 will be between RMB 1,807.6 billion and RMB 1,873.2 billion, compared with approximately RMB 6 for the year ended 31 December 2022.
NH HEALTH: POSITIVE PROFIT ALERT
Zheshang Securities: What are the marginal changes and investment logic of the pharmaceutical sectors in 2023Q4?
The Zhitong Finance App learned that against the backdrop of high base figures for some products in the 2022 Q4 and 2023Q1 pharmaceutical sector, the bank is more optimistic about digesting undervaluation and investment opportunities with the logic of going overseas.
New Horizon Health Limited (HKG:6606) Not Flying Under The Radar
When you see that almost half of the companies in the Healthcare industry in Hong Kong have price-to-sales ratios (or "P/S") below 1.1x, New Horizon Health Limited (HKG:6606) looks to be giving off st
CITIC Securities: Healthcare Faces Deepening Changes and Focusing on Seven Major Prospects of Industrial Trends
CITIC Securities released a research report saying that in 2023 in the post-pandemic era, the healthcare industry ushered in the harshest anti-corruption storm in nearly 20 years. Combined with frequent biomedical industry policies in recent years, industrial development has ushered in profound changes, and sector valuations and public fund allocations are also at historically relatively low levels.
Guojin Securities: Sector-suppressing factors, clear pharmaceuticals are expected to welcome a major inflection point in the reversal of economic sentiment
The Zhitong Finance app learned that Guojin Securities released a research report saying that after a long period of decline and adjustment, the pharmaceutical sector ushered in a major inflection point from the second half of 2023 to 2024, and various factors such as policy, performance, and chips bottomed out and reversed.
Guoxin Securities's 24-year Pharmaceutical Strategy: Good Timing+High Returns, Positioning the Second Wave of Global Innovation Leaders
Guoxin Securities believes that 2023Q4 is the best time to lay out the pharmaceutical market for the next three years.
Institutional Investors in New Horizon Health Limited (HKG:6606) Lost 8.1% Last Week but Have Reaped the Benefits of Longer-term Growth
Key Insights Given the large stake in the stock by institutions, New Horizon Health's stock price might be vulnerable to their trading decisions The top 9 shareholders own 51% of the company Insi
Changes in Hong Kong stocks | Novartis Health (06606) rose nearly 7% again, up more than 30% during the month, Double Eleven e-commerce sales exceeded 80 million
Nuohui Health (06606) rose nearly 7% again, rising more than 30% during the month. As of press release, it rose 6.62% to HK$24.95, with a turnover of HK$71.764,400.
No Data